Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades

Published 14/03/2024, 13:35
© Reuters. The logo of the Spanish pharmaceuticals company Grifols is pictured on its facilities in Parets del Valles, north of Barcelona, Spain, January 9, 2024. REUTERS/Albert Gea/File Photo
GRLS
-

(Reuters) -Shares in Grifols fell more than 9% on Thursday after credit rating agencies Fitch and S&P downgraded their ratings for the beleaguered Spanish drugmaker, citing lower than expected free cash flow generation and refinancing risks.

The company's shares were down 9.1% at 1400 GMT, the worst performers in Spain's blue-chip index, which was down 0.28%.

Fitch said its downgrade to "B+" from "BB-", both in the so-called speculative part of the rating scale, reflected Grifols' "slower-than-expected deleveraging, caused by significantly lower free cash flow generation in 2023 and 2024 than previously forecast by Fitch".

However, the agency added that a successful sale of Grifols' 20% stake in Shanghai RAAS, which is pending regulatory approval and the company expects to close in the first half of 2024, "would help mitigate refinancing pressure".

Meanwhile, S&P lowered its rating to "B" from "B+" as it also highlighted the Spanish company's weaker cash flow generation and higher refinancing risks.

Grifols said in a statement that the downgrades came "in light of 2025 maturities" that it expected to address in the first half of this year to improve leverage levels, adding that it would continue to conduct business as usual.

"Rating agencies typically adopt a conservative stance without considering the current status of the efforts and advancements that Grifols is making to address such debt," it said.

On March 1, Grifols announced a new operating cash flow generation target for 2024, expecting it to more than double to 900 million euros ($984 million) before one-off items this year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company is also seeking to generate between 2 billion and 2.5 billion euros in free cash flow before dividends from 2025 to 2027. In 2023 it posted negative free cash flow for the second straight year.

Since early January, a report by short-seller fund Gotham City Research that questioned Grifols' accounting and debt ratio has cast doubts about the company's business and wiped off billions of euros in market value.

On March 8, Grifols received a boost when auditor KPMG approved the company's 2023 results without modifying its reported profit and debt ratio.

Neither Fitch nor S&P made any reference to Gotham City's report.

($1 = 0.9142 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.